Search filters
Filters
Clear All

Phase

  • 59
  • 97
  • 108
  • 89
  • 14
  • 169
  • 697
  • 454
  • 14
  • 32
  • 1
  • 4
  • 648

Found 699 none trials

A listing of none medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A PHASE II RANDOMIZED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF FECAL MICROBIOTA TRANSPLANTATION USING THE PENN MICROBIOME THERAPY PRODUCTS FOR SEVERE OR SEVERE-COMPLICATED/FULMINANT CLOSTRIDIUM DIFFICILE INFECTION

99 years or below
All genders
Phase 2
Learn More

A Phase 1 Open-Label Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients with Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma

99 years or below
All genders
Phase 1
Multi-center, open-label, first in human (FIH) Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CARTTnMUC1 cells). …
Learn More

UPCC 10219: Phase II Study Of Stromal Changes Detected By DCE- and DW-MRI In Response To PEGPH20 Combined With Chemotherapy In Subjects With Locally-Advanced Pancreatic Cancer

99 years or below
All genders
Phase 2
The research study is being conducted to determine the effects of PEGPH20 plus chemotherapy treatment on the MRI characteristics of pancreatic cancer tumors. Subjects will receive Gemcitabine, Abraxane, and PEGPH20.
Learn More
A Phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma

A Phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma

18 years - 90 years
All genders
Phase 2
Non-Hodgkin lymphoma is a disease that can be treated effectively with chemotherapy and immunotherapy, but relapses can occur. The purpose of this study is to research the use of a new radioimmunotherapy drug called Betalutin®. Betalutin® is made by using a new antibody, called lilotomab, and attaching a radioactive molecule …
Learn More
Study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 subjects with Leber's Congenital Amourosis (LCA) Due to to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene.

Study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 subjects with Leber's Congenital Amourosis (LCA) Due to to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene.

18 years - 90 years
All genders
Interventional
You are invited to take part in a research study for with the investigational drug, QR-110 (referred to as “the study drug”) for Leber's Congenital Amourosis . Currently there is no approved treatment for LCA10. The study drug is designed to repair the problem that causes LCA10. This may stop …
Learn More

Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive Advanced Kinase Inhibitor Naive RET-Mutant Medullary Thyroid Cancer

18 years - 99 years
All genders
Phase 3
Learn More
Clinical research study to assess ability of eltrombopag to induce sustained remission in subjects with Immune Thrombocytopenia who are refractory or relapsed after first line steroids TAPER

Clinical research study to assess ability of eltrombopag to induce sustained remission in subjects with Immune Thrombocytopenia who are refractory or relapsed after first line steroids TAPER

18 years - 99 years
All genders
Phase 2
This research study is to find out if the study drug eltrombopag also known as Revolade/Promacta can help those who have Immune Thrombocytopenia (ITP.)  The study will determine if subjects are able to stop eltrombopag treatment while maintaining acceptable platelet levels after their disease has become resistant to treatment or …
Learn More
A Study to Evaluate the Safety and Feasibility of Exablate Model 4000 Type-2 to temporarily mediate Blood-Brain Barrier Disruption (BBBD) in patients with suspected infiltrating glioma in the setting of planned surgical interventions

A Study to Evaluate the Safety and Feasibility of Exablate Model 4000 Type-2 to temporarily mediate Blood-Brain Barrier Disruption (BBBD) in patients with suspected infiltrating glioma in the setting of planned surgical interventions

18 years - 99 years
All genders
The goal of this prospective, non-randomized, single-arm study is to evaluate the safety and feasibility of using ExAblate Model 4000 Type-2 Neuro-System as a tool to disrupt the blood brain barrier in a temporary and localized fashion in patients with suspected infiltrating glioma undergoing planned surgical interventions.
Learn More

UPCC 03621: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B (Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

99 years or below
All genders
TBD
Learn More

UPCC 04621: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02C (Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy

99 years or below
All genders
TBD
Learn More
331 - 340 of 699